03064nas a2200349   4500000000100000008004100001653001000042653001100052653001100063653000900074653000900083653002200092653001600114653001700130653004900147653002600196653003600222653005800258100002000316700001800336700001300354700001400367700001500381700001600396700001600412245012200428250001500550300001100565490000700576520208000583020005102663       2014                            d10aAdult10aFemale10aHumans10aAged10aMale10aTreatment Outcome10aMiddle Aged10aTime Factors10aFibrinolytic Agents/ administration & dosage10aKaplan-Meier Estimate10aStroke/ drug therapy/ mortality10aTissue Plasminogen Activator/ administration & dosage1 aLindley Richard1 aSandercock P.1 aCohen G.1 aMurray G.1 aWardlaw J.1 aWhiteley W.1 aThompson D.00aEffect of alteplase within 6 hours of acute ischemic stroke on all-cause mortality (third International Stroke Trial)  a2014/11/06  a3612-70 v453 a<p>
BACKGROUND AND PURPOSE: Prompt thrombolytic therapy with intravenous alteplase reduces disability after acute ischemic stroke. In an exploratory analysis, we examined whether long-term survival varied by baseline characteristics after alteplase. METHODS: In this open-treatment, international, randomized, controlled trial, ischemic stroke patients were randomly allocated &lt;6 hours of onset to intravenous alteplase (0.9 mg/kg) plus standard care (n=1515) or standard care alone (n=1520). We followed patients to death, censoring when last known to be alive. We grouped patients by delay to randomization, and good or poor predicted prognosis (calculated from baseline National Institutes of Health Stroke Scale [NIHSS] score and age). We present absolute mortality differences between treated and control groups at 7 days, 6 months, and 18 months poststroke. RESULTS: Alteplase was not associated with a significant increase in mortality within 18 months (0.6% [95% confidence interval (CI), -2.9% to +4.2] P=0.72] in all patients with complete vital status (99.9%, 3034/3035). In patients randomized &lt;3 hours of stroke, 18-month mortality was lower in the alteplase-treated group than the control group (40.6% [95% CI, 42.6-52.7] versus 47.8% [95% CI, 35.5-45.3]; P=0.0434]. The difference in 18-month mortality between alteplase-treated and control patients was greater in patients who were randomized early (&lt;3 hours) compared with late (3-6 hours; +9% [95% CI, 1-17]; P=0.0317). Alteplase led to a greater improvement in 18-month survival in patients with a poor prognosis than in patients with a good prognosis (+8% [95% CI, 2-14]; P=0.0091). CONCLUSIONS: These exploratory analyses of the third International Stroke Trial (IST-3) trial support improving acute stroke patients' access to earlier alteplase treatment, treatment of patients with poor prognosis, and further randomized controlled trials in minor stroke to replicate these findings. CLINICAL TRIAL REGISTRATION URL: http://www.controlled-trials.com. Unique identifier: ISRCTN25765518.
</p>
  a1524-4628 (Electronic)<br/>0039-2499 (Linking)